200 related articles for article (PubMed ID: 9581697)
1. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group.
Kasahara A; Hayashi N; Mochizuki K; Takayanagi M; Yoshioka K; Kakumu S; Iijima A; Urushihara A; Kiyosawa K; Okuda M; Hino K; Okita K
Hepatology; 1998 May; 27(5):1394-402. PubMed ID: 9581697
[TBL] [Abstract][Full Text] [Related]
2. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.
Tanaka H; Tsukuma H; Kasahara A; Hayashi N; Yoshihara H; Masuzawa M; Kanda T; Kashiwagi T; Inoue A; Kato M; Oshima A; Kinoshita Y; Kamada T
Int J Cancer; 2000 Sep; 87(5):741-9. PubMed ID: 10925370
[TBL] [Abstract][Full Text] [Related]
3. Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus.
Hung CH; Lee CM; Wang JH; Tung HD; Chen CH; Lu SN
J Gastroenterol Hepatol; 2005 Oct; 20(10):1553-9. PubMed ID: 16174073
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up study of sustained biochemical responders with interferon therapy.
Shindo M; Hamada K; Oda Y; Okuno T
Hepatology; 2001 May; 33(5):1299-302. PubMed ID: 11343259
[TBL] [Abstract][Full Text] [Related]
5. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
[TBL] [Abstract][Full Text] [Related]
6. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
Shindo M; Ken A; Okuno T
Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Koyama R; Hosaka T; Sezaki H; Kobayashi M; Kumada H
Intervirology; 2007; 50(1):16-23. PubMed ID: 17164553
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics of patients with chronic hepatitis C showing biochemical remission, without hepatitis C virus eradication, as a result of interferon therapy. The Osaka Liver Disease Study Group.
Kasahara A; Hayashi N; Mochizuki K; Hiramatsu N; Sasaki Y; Kakumu S; Kiyosawa K; Okita K
J Viral Hepat; 2000 Sep; 7(5):343-51. PubMed ID: 10971822
[TBL] [Abstract][Full Text] [Related]
9. Long-term responders without eradication of hepatitis C virus after interferon therapy: characterization of clinical profiles and incidence of hepatocellular carcinoma.
Yabuuchi I; Imai Y; Kawata S; Tamura S; Noda S; Inada M; Maeda Y; Shirai Y; Fukuzaki T; Kaji I; Ishikawa H; Matsuda Y; Nishikawa M; Seki K; Matsuzawa Y
Liver; 2000 Jul; 20(4):290-5. PubMed ID: 10959807
[TBL] [Abstract][Full Text] [Related]
10. Natural course of asymptomatic hepatitis C virus-infected patients and hepatocellular carcinoma after interferon therapy.
Okanoue T; Minami M; Makiyama A; Sumida Y; Yasui K; Itoh Y
Clin Gastroenterol Hepatol; 2005 Oct; 3(10 Suppl 2):S89-91. PubMed ID: 16234069
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy.
Tokita H; Fukui H; Tanaka A; Kamitsukasa H; Yagura M; Harada H; Okamoto H
J Gastroenterol Hepatol; 2005 May; 20(5):752-8. PubMed ID: 15853990
[TBL] [Abstract][Full Text] [Related]
12. Interferon retreatment reduces or delays the incidence of hepatocellular carcinoma in patients with chronic hepatitis C.
Hino K; Kitase A; Satoh Y; Fujiwara D; Yamaguchi Y; Korenaga M; Shingai Y; Konishi T; Yamashita S; Uchida K; Mori K; Hanada H; Kodama T; Nukui K; Okita K
J Viral Hepat; 2002 Sep; 9(5):370-6. PubMed ID: 12225332
[TBL] [Abstract][Full Text] [Related]
13. Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy.
Oze T; Hiramatsu N; Yakushijin T; Miyazaki M; Yamada A; Oshita M; Hagiwara H; Mita E; Ito T; Fukui H; Inui Y; Hijioka T; Inada M; Katayama K; Tamura S; Yoshihara H; Inoue A; Imai Y; Hayashi E; Kato M; Miyagi T; Yoshida Y; Tatsumi T; Kasahara A; Hamasaki T; Hayashi N; Takehara T;
Clin Gastroenterol Hepatol; 2014 Jul; 12(7):1186-95. PubMed ID: 24321207
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy.
Iwasaki Y; Takaguchi K; Ikeda H; Makino Y; Araki Y; Ando M; Kobashi H; Kobatake T; Tanaka R; Tomita M; Senoh T; Kawaguchi M; Shimoe T; Manabe K; Kita K; Shimamura J; Sakaguchi K; Shiratori Y
Liver Int; 2004 Dec; 24(6):603-10. PubMed ID: 15566511
[TBL] [Abstract][Full Text] [Related]
15. Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection.
Arase Y; Ikeda K; Tsubota A; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Sezaki H; Kobayashi M; Kumada H
Intervirology; 2004; 47(6):355-61. PubMed ID: 15564748
[TBL] [Abstract][Full Text] [Related]
16. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group.
Imai Y; Kawata S; Tamura S; Yabuuchi I; Noda S; Inada M; Maeda Y; Shirai Y; Fukuzaki T; Kaji I; Ishikawa H; Matsuda Y; Nishikawa M; Seki K; Matsuzawa Y
Ann Intern Med; 1998 Jul; 129(2):94-9. PubMed ID: 9669992
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome, with monitoring of platelet counts, in patients with chronic hepatitis C and liver cirrhosis after interferon therapy.
Moriyama M; Matsumura H; Aoki H; Shimizu T; Nakai K; Saito T; Yamagami H; Shioda A; Kaneko M; Goto I; Tanaka N; Arakawa Y
Intervirology; 2003; 46(5):296-307. PubMed ID: 14555850
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis G infection and therapeutic response to interferon in HCV-related chronic liver disease.
Pramoolsinsap C; Poovorawan Y; Sura T; Theamboonlers A; Busagorn N; Kurathong S
Southeast Asian J Trop Med Public Health; 1998 Sep; 29(3):480-90. PubMed ID: 10437943
[TBL] [Abstract][Full Text] [Related]
19. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study.
Ikeda K; Marusawa H; Osaki Y; Nakamura T; Kitajima N; Yamashita Y; Kudo M; Sato T; Chiba T
Ann Intern Med; 2007 May; 146(9):649-56. PubMed ID: 17470833
[TBL] [Abstract][Full Text] [Related]
20. A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development.
Kashiwagi K; Furusyo N; Kubo N; Nakashima H; Nomura H; Kashiwagi S; Hayashi J
J Infect Chemother; 2003 Dec; 9(4):333-40. PubMed ID: 14691655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
